ST-Segment Elevation Myocardial Infarction
- PMID: 11792225
- DOI: 10.1007/s11936-002-0023-3
ST-Segment Elevation Myocardial Infarction
Abstract
ST-segment elevation myocardial infarction (MI) is an emergency medical condition. Expediting the steps leading to coronary reperfusion is of critical importance in improving survival after acute MI. After the diagnosis of acute MI is made, patients should be treated with oxygen, aspirin, nitroglycerin, beta-blockers, heparin, and analgesics, barring any contraindications. If an experienced cardiac catheterization laboratory is available within 60 to 90 minutes, then catheter-based reperfusion therapy is recommended; otherwise, thrombolysis should be considered as an alternate therapy. Therapy with a reduced-dose thrombolytic agent and a glycoprotein IIb/IIIa receptor inhibitor appears to be of an added benefit in establishing TIMI (Thrombolysis in Myocardial Infarction) 3 flow, but this approach awaits final approval prior to widespread use. The adjunctive use of glycoprotein IIb/IIIa receptor inhibitors with percutaneous transluminal coronary angioplasty, with or without stenting, appears to be beneficial and is being used more frequently in the acute setting. Coronary angiography should be performed in patients who fail to respond to thrombolytic therapy or who have evidence of recurrent ischemia. This procedure should not be routinely performed in patients who have responded to thrombolytic therapy. Four to 6 days after an acute MI event, assessment of left ventricular function is recommended. Submaximal exercise test (with or without nuclear or echocardiographic imaging) should be considered in patients prior to discharge from the hospital--an exception can be made in patients with one-vessel disease treated successfully with percutaneous transluminal coronary angioplasty. After discharge, a regular exercise test should be obtained 4 to 6 weeks after an uncomplicated acute MI event. Secondary prevention measures such as weight loss, cessation of smoking, aspirin, beta-blockers, lipid-lowering agents, and angiotensin-converting enzyme inhibitors should be considered in all patients, barring contraindications.
Similar articles
-
The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends.Am J Cardiol. 2000 Apr 27;85(8A):32C-8C. doi: 10.1016/s0002-9149(00)00877-8. Am J Cardiol. 2000. PMID: 10793178 Review.
-
Contemporary NSTEMI management: the role of the hospitalist.Hosp Pract (1995). 2020 Feb;48(1):1-11. doi: 10.1080/21548331.2020.1701329. Epub 2020 Feb 20. Hosp Pract (1995). 2020. PMID: 31815570 Review.
-
Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.Ital Heart J. 2001 Oct;2(10):751-6. Ital Heart J. 2001. PMID: 11721719 Clinical Trial.
-
Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the thrombolysis in myocardial infarction (TIMI) 14 trial.Am Heart J. 2003 Jul;146(1):42-7. doi: 10.1016/S0002-8703(03)00145-5. Am Heart J. 2003. PMID: 12851606 Clinical Trial.
-
Reperfusion strategies in acute ST-elevation myocardial infarction: an overview of current status.Prog Cardiovasc Dis. 2008 Mar-Apr;50(5):352-82. doi: 10.1016/j.pcad.2007.11.004. Prog Cardiovasc Dis. 2008. PMID: 18313480 Review.
Cited by
-
Beneficial effects of combined administration of Clopidogrel and Aspirin on the levels of proinflammatory cytokines, cardiac function, and prognosis in ST-segment elevation myocardial infarction: A comparative study.Medicine (Baltimore). 2018 Nov;97(45):e13010. doi: 10.1097/MD.0000000000013010. Medicine (Baltimore). 2018. PMID: 30407292 Free PMC article. Clinical Trial.
References
LinkOut - more resources
Full Text Sources